Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.

Sponsor
Case Comprehensive Cancer Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05106192
Collaborator
(none)
22
1
2
21
1

Study Details

Study Description

Brief Summary

A study to compare pain differences between using MedJet needle-free drug-delivery system with standard of care treatment for cutaneous T-cell lymphomas and cutaneous B-cell lymphomas in participants.

Condition or Disease Intervention/Treatment Phase
  • Device: Med-Jet Injector
  • Drug: Triamcinolone Acetonide
  • Drug: Bexarotene 1% Top Gel
  • Drug: Nitrogen Mustard
  • Device: Conventional syringe
N/A

Detailed Description

Participants will undergo treatments on two morphologically and anatomically matched target lesions, preferably on opposing sides of the body.

The first plaque will be treated using standard of care topical bexarotene or nitrogen mustard for participants with CTCL (cutaneous T-cell lymphomas) or intralesional TAC (triamcinolone acetonide) using a syringe/needle with participants with CBCL (cutaneous B-cell lymphomas).

The second plaque will be treated using a needle-free injector system. After the treatment, the participants will be followed for another three visits over the course of 4 months to see how the treated areas responded.

In order to account for 20% dropout, 11 patients per group (a needle free and a traditional treatment group in CBCL patients and the same two groups in CTCL patients) will be recruited.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
22 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.
Anticipated Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2023
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cutaneous T-cell lymphomas (CTCL) Participants

The first plaque will be treated using standard of care topical bexarotene or nitrogen mustard for participants with CTCL (cutaneous T-cell lymphomas) The second plaque will be treated using a needle-free injector system. After the treatment, the participants will be followed for another three visits over the course of 4 months to see how the treated areas responded.

Device: Med-Jet Injector
The Med-Jet injector is a needle-free injection system that consists of a hand-held firing body/trigger, sterilized barrel, disposable luer lock syringe, disposable nozzle cap, and disposable splash guard. The Med-Jet injector is designed to deliver drugs or biologics into the intradermal, subcutaneous, or intramuscular tissues, by means of a narrow, high-velocity jet of fluid, which penetrates the surface of the skin and delivers the fluid to the target tissue

Drug: Triamcinolone Acetonide
The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.20 ml of injected fluid).

Drug: Bexarotene 1% Top Gel
Bexarotene can be applied up to four times daily according to patient tolerance directly to lesions. The gel is 1% bexarotene concentration.

Drug: Nitrogen Mustard
Nitrogen mustard is applied once daily as patient tolerates. It is sold in a concentration of 0.016% gel.

Experimental: Cutaneous B-cell lymphomas (CBCL) Participants

The first plaque will be treated using standard of care intralesional TAC (triamcinolone acetonide) using a syringe/needle with participants with CBCL (cutaneous B-cell lymphomas). The second plaque will be treated using a needle-free injector system. After the treatment, the participants will be followed for another three visits over the course of 4 months to see how the treated areas responded.

Device: Med-Jet Injector
The Med-Jet injector is a needle-free injection system that consists of a hand-held firing body/trigger, sterilized barrel, disposable luer lock syringe, disposable nozzle cap, and disposable splash guard. The Med-Jet injector is designed to deliver drugs or biologics into the intradermal, subcutaneous, or intramuscular tissues, by means of a narrow, high-velocity jet of fluid, which penetrates the surface of the skin and delivers the fluid to the target tissue

Drug: Triamcinolone Acetonide
The target lesion will be wiped with alcohol and injected with 10mg/ml of TAC directed towards the dermis to create a blanching wheal that is 1 cubic centimeter (total of 0.20 ml of injected fluid).

Device: Conventional syringe
A standard sterile disposable 1 ml syringe and 30-gauge needle will be used to inject TAC.

Outcome Measures

Primary Outcome Measures

  1. Pain measurement between the Med-Jet and standard of care treatment. [1.5 Hour after the treatment]

    The pain of injections with Medjet vs conventional topical therapies of bexarotene or nitrogen mustard will be measured using a visual standard analog pain scale 0 (no distress) to 10 (unbearable distress) immediately after each injection.

Secondary Outcome Measures

  1. Participants Preference [3 Months]

    Number of participants that prefer traditional treatment versus MedJet.

  2. Tolerability of Pruritus [At Baseline, 1 month, 2 months, and 3 months]

    Tolerability will be measured using Pruritus score assessment in the Medjet and topical therapy cohorts using a visual standard analog itching scale 0 (no itch) to 10 (worst itch imaginable) with the affected plaques at each indicated visit.

  3. Quality of life due to skin conditions [3 Months]

    The quality of life assessment will be done using the Dermatology Life Quality Index survey (DLQI) which will include a series of topics related to the skin condition including symptoms, feelings, effects on daily life, employment or schooling, personal relationships, and treatment. Each of the ten (10) questions are scored from 0 to 3, giving a score range from 0 (meaning no impact of skin disease on quality of life) to 30 (meaning maximum impact on quality of life). Resulting scores are as follows: 0-1 = No effect on patient's life, 2-5 = Small effect, 6-10 = Moderate effect, 11-20 = Very large effect, 21-30 = Extremely large effect.

  4. CAILS assessment of clinical efficacy [At Baseline, 1 month, 2 months, and 3 months]

    Composite Assessment of Index Lesion Severity (CAILS) is an assessment of individual lesions by the investigator of disease severity at the time of evaluation which can be used to monitor and compare lesions over time. CAILS is a 5-criterion scale ranging from 0 (no evidence) to 8 (severe), incorporating an assessment of the size of the lesion and severity of erythema, scaling, plaque elevation, and hypo- or hyperpigmentation. When making the assessment of severity, the Investigator will score the area with most clearance (ie, have scores of 0) within the treated plaque.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. 18 years of age

  2. Diagnosed with primary cutaneous lymphoma defined by either:

  • A board-certified dermatologist, OR

  • Dermatology Nurse Practitioner, OR

  • Skin punch biopsy

  1. The presence of plaque-type primary cutaneous lymphoma lesions with at least two plaques that are at least two cm² in areas of the trunk, buttocks, or extremities that are either:
  • Symmetrically located on contralateral body site OR

  • Within the same body site but separated by ≥ 1 cm

  • Both plaques must be similar in size as much as possible

  1. Able to give informed consent under IRB approval procedures
Exclusion Criteria:
  1. Known allergy or hypersensitivity to triamcinolone acetonide

  2. Known allergy to topical bexarotene or topical nitrogen mustard

  3. Pregnant, breastfeeding, or planning to get pregnant 4 weeks before, during, and 4 weeks after the study.

  4. Inability to provide informed consent

  5. Diagnosis of erythrodermic mycosis fungoides or Sezary syndrome

  6. Use of topical corticosteroids to target lesions within 1 week prior to baseline visit

  7. Use of radiation therapy to target lesions within 1 week prior to baseline visit

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland Ohio United States 44106

Sponsors and Collaborators

  • Case Comprehensive Cancer Center

Investigators

  • Principal Investigator: Kevin Cooper, MD, Case Comprehensive Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT05106192
Other Study ID Numbers:
  • CASE4621
First Posted:
Nov 3, 2021
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022